Pfizer's Lorlatinib Scores European Approval In ALK-Positive Lung Cancer

Loading...
Loading...

The European Commission has approved Pfizer Inc's PFE Lorviqua (lorlatinib) for a form of advanced non-small-cell lung cancer (NSCLC).

  • Lorlatinib is available in the U.S. under the brand name Lorbrena.
  • The approval covers lorlatinib as monotherapy for anaplastic lymphoma kinase (ALK)- positive advanced NSCLC previously not treated with an ALK inhibitor. 
  • Related: Pfizer's Lorbrena Wins Full FDA Approval As First-Line Treatment Of ALK-Positive Lung Cancer.
  • The approval for the first-line use is based on the pivotal Phase 3 CROWN trial results, in which Lorviqua reduced the risk of disease progression or death by 72% compared to Xalkori (crizotinib). 
  • As a secondary endpoint, the confirmed objective response rate (ORR) was 76% with Lorviqua and 58% with Xalkori. 
  • Price Action: PFE shares are up 2.16% at $54.52 during the market session on the last check Friday.
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsNon-Small Cell Lung Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...